In conclusion, our study shows that PON1 Q192R genotype does not modify the efficacy and safety of clopidogrel in patients with acute coronary syndromes.
We evaluated the possible relationships of HDL levels as well as PON-1 activities and the Q192R genotype with clopidogrel's antiplatelet efficacy in acute coronary syndrome (ACS) patients.